Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Omrix Fibrin Pad Follow Up Email, July 10, 2012 - EVARREST

Tilghman, Tracy

From:                                Lindsey, Kimberly

Sent:                                 Tuesday, July 10, 2012 1:47 PM

To:                                     Tilghman, Tracy; Ananyeva, Natalya

Cc:                                     Barash, Faith; Brown, La'Nissa; Golding, Basil; Mintz, Paul

Subject:                             Omrix Fibrin Pad follow up items (PMR/PMC) for immunogenicity and repeat exposure


Dear All,

At the end of the midcycle meeting there were two outstanding clinical items regarding PMR/PMC:

·      Is a PMR needed for immunogenicity?

·      Is a PMR needed for repeat exposure?


I discussed the issues with the DH management in attendance for the midcycle meeting (Drs. Basil Golding and Paul



They are in agreement that since Omrix has an ongoing US program to obtain a general adjunct to hemostasis indication, the immunogenicity information can be obtained during the ongoing US clinical development program. Omrix will be collecting immunogenicity information in a recently submitted IND (---b(4)------------------------------------------------------------------------------. In addition, they collected immunogenicity information in their non US studies. This information is in the BLA currently under review.


As for the repeat exposure, in our advice letter for IND –b(4)- sent to Omrix on June 29, 2012, we asked Omrix to submit a repeat dose toxicity preclinical study.

Page Last Updated: 01/03/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English